A. Rachel Leheny Buys 20,000 Shares of CalciMedica, Inc. (NASDAQ:CALC) Stock

CalciMedica, Inc. (NASDAQ:CALC) CEO A. Rachel Leheny purchased 20,000 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $3.75 per share, with a total value of $75,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 130,926 shares of the company’s stock, valued at $490,972.50. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A. Rachel Leheny also recently made the following trade(s):

• On Tuesday, August 27th, A. Rachel Leheny bought 1,000 shares of CalciMedica stock. The stock was bought at an average price of $4.19 per share, with a total value of $4,190.00.

CalciMedica Trading Down 5.1 %

CALC stock opened at $3.51 on Friday. CalciMedica, Inc. has a 12 month low of $2.14 and a 12 month high of $8.38. The company has a fifty day moving average price of $4.25 and a 200 day moving average price of $4.63.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.03. Analysts forecast that CalciMedica, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc increased its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 as of its most recent SEC filing.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of CalciMedica in a research report on Tuesday, August 13th. Oppenheimer boosted their target price on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, July 10th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.